These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 25645356)

  • 21. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Moskowitz AJ; Ghione P; Jacobsen E; Ruan J; Schatz JH; Noor S; Myskowski P; Vardhana S; Ganesan N; Hancock H; Davey T; Perez L; Ryu S; Santarosa A; Dowd J; Obadi O; Pomerantz L; Yi N; Sohail S; Galasso N; Neuman R; Liotta B; Blouin W; Baik J; Geyer MB; Noy A; Straus D; Kumar P; Dogan A; Hollmann T; Drill E; Rademaker J; Schoder H; Inghirami G; Weinstock DM; Horwitz SM
    Blood; 2021 Dec; 138(26):2828-2837. PubMed ID: 34653242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
    Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
    Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
    Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
    Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
    [No Abstract]   [Full Text] [Related]  

  • 24. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1.
    Celik EG; Eroglu O
    Mol Biol Rep; 2024 Jul; 51(1):832. PubMed ID: 39037638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JAK3
    Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
    Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic analysis of patients with mutations in the JAK/STAT signaling pathway in adult acute lymphoblastic leukemia].
    Fan WJ; Xu TT; Guo JJ; Li YF; Jiang ZX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):594-597. PubMed ID: 34455748
    [No Abstract]   [Full Text] [Related]  

  • 29. CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
    Walker KL; Rinella SP; Hess NJ; Turicek DP; Kabakov SA; Zhu F; Bouchlaka MN; Olson SL; Cho MM; Quamine AE; Feils AS; Gavcovich TB; Rui L; Capitini CM
    Leuk Lymphoma; 2021 May; 62(5):1167-1177. PubMed ID: 33843403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
    Gallipoli P; Cook A; Rhodes S; Hopcroft L; Wheadon H; Whetton AD; Jørgensen HG; Bhatia R; Holyoake TL
    Blood; 2014 Aug; 124(9):1492-501. PubMed ID: 24957147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
    Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
    Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.
    Ziętara KJ; Wróblewska K; Zajączkowska M; Taczała J; Lejman M
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
    Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
    Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
    Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
    Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
    Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
    Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
    Migita K; Izumi Y; Torigoshi T; Satomura K; Izumi M; Nishino Y; Jiuchi Y; Nakamura M; Kozuru H; Nonaka F; Eguchi K; Kawakami A; Motokawa S
    Clin Exp Immunol; 2013 Dec; 174(3):356-63. PubMed ID: 23968543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
    Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
    Front Immunol; 2020; 11():620098. PubMed ID: 33658996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
    van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
    Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.